Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03834519 |
| Consolidated Lead Sponsor | Merck & Co. |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 793 participants (ACTUAL) |
| Registered Start Date | 2019-05-02 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UCLA Health and Jonsson Comprehensive Cancer Center | Los Angeles, CA | Open Hospital Dossier -> |
| Johns Hopkins Hospital and Kimmel Cancer Center | Baltimore, MD | Open Hospital Dossier -> |
| Beth Israel Deaconess Medical Center | Boston, MA | Open Hospital Dossier -> |
| Dana-Farber Cancer Institute | Boston, MA | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.